Cybin (CYBN) announced that it has received approval from the UK Medical and Healthcare Products Regulatory Agency to commence EMBRACE, the second pivotal study in Paradigm, the company’s Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The company previously received Breakthrough Therapy Designation from the FDA for CYB003 for the adjunctive treatment of Major Depressive Disorder.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Inc. Expands Market Strategy with New SEC Filing
- Cybin Inc. Secures $50 Million in Convertible Debenture Deal
- Cybin’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
- Cybin price target lowered to $70 from $73 at Canaccord
- Cybin Inc. Reports on Governance and Compliance